フルオキセチンの世界市場レポート 2025年

フルオキセチンの市場規模は、今後数年間で安定した成長が見込まれます。2029年には年間平均成長率（CAGR）4.7％で12億5,000万米ドルに成長します。予測期間の成長は、メンタルヘルスプログラムに対する政府の取り組みや資金提供、心の健康を促進する公衆衛生キャンペーン、ソーシャルメディアプラットフォームにおけるメンタルヘルス問題に関する議論や意識の高まり、オンライン薬局の台頭、メンタルヘルス問題を受け入れ、対処する文化的シフトなどに起因すると考えられます。予測期間における主な動向としては、早期発見につながる診断方法の進歩、遠隔医療の台頭、ドラッグデリバリーシステムの進歩、創薬・薬剤開発におけるAIや機械学習の利用拡大、薬理ゲノミクスの開発などが挙げられます。

精神疾患の罹患率の増加は、今後のフルオキセチン市場の拡大を促進すると予想されます。メンタルヘルス障害は、認知機能、感情機能、行動機能に影響を及ぼし、日常生活における苦痛や障害をもたらす幅広い症状を包含します。これらの疾患増加の要因としては、社会的圧力、経済的課題、ライフスタイルの変化、認知・診断の向上などが挙げられます。フルオキセチンは、気分や感情の調節に重要な脳内セロトニン濃度を高めることで症状を緩和するため、精神疾患の治療に利用されています。例えば、2022年11月に英国政府出資のヘルスケアシステムであるNational Health Serviceが実施した調査によると、2022年には7歳から16歳の子供の約18.0％、17歳から24歳の若者の約22.0％が精神障害の可能性があることが明らかになりました。特に、17歳から19歳の若者の精神障害の可能性のある有病率は、2021年の17.4％から2022年には25.7％に増加しました。その結果、精神疾患の有病率の上昇は、フルオキセチン市場の成長を促進する重要な要因となっています。

フルオキセチン市場は、ヘルスケア支出の増加による成長が見込まれています。この増加の背景には、先端医療技術のコスト高騰、高齢化、慢性疾患の蔓延といった要因があります。ヘルスケア支出の増加に伴い、フルオキセチンのような医薬品へのアクセスや購入のしやすさが改善され、うつ病や不安障害の治療が必要な患者にとっては、アクセスや服薬アドヒアランスの向上がメリットとなります。その結果、全体的なメンタルヘルスのアウトカムが改善し、長期的なヘルスケア費用が削減されます。例えば、2024年1月、米国のヘルスケア支出は2022年に4.1％増の4兆5,000億米ドルに急増し、2021年の3.2％増に比べ成長率が加速したと、米国政府機関National Institutes of Healthが報告しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界フルオキセチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のフルオキセチン市場：成長率分析
• 世界のフルオキセチン市場の実績：規模と成長, 2019-2024
• 世界のフルオキセチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界フルオキセチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のフルオキセチン市場剤形別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 錠剤
• ソリューション
• カプセル
• シロップ
• その他の剤形
• 世界のフルオキセチン市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• その他の投与経路
• 世界のフルオキセチン市場人口統計別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 成人用
• 小児科
• 高齢者
• 世界のフルオキセチン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 強迫性障害
• パニック障害
• うつ
• 神経性過食症
• その他の用途
• 世界のフルオキセチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クリニック
• 病院
• その他のエンドユーザー
• 世界のフルオキセチン市場タブレットの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• レギュラータブレット
• 徐放錠
• 世界のフルオキセチン市場ソリューションのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口溶液
• 世界のフルオキセチン市場カプセルのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標準カプセル
• 遅延放出カプセル
• 世界のフルオキセチン市場シロップの種類別細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口シロップ
• 世界のフルオキセチン市場その他の剤形のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射剤
• 局所形式

第7章 地域別・国別分析

• 世界のフルオキセチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のフルオキセチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• フルオキセチン市場：競合情勢
• フルオキセチン市場：企業プロファイル
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Hetero Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Torrent Pharmaceuticals GmbH
• Aurobindo Pharma
• Cadila Pharmaceuticals Ltd.
• Dr. Reddy's Laboratories Limited
• Apotex Inc.
• Amneal Pharmaceuticals Inc.
• Lupin Ltd.
• Glenmark Pharmaceuticals Inc.
• Alvogen
• Alembic Pharmaceuticals Limited
• Accord Healthcare Ltd.
• PERRIGO Company plc
• Wockhardt Ltd.
• Jubilant Life Sciences Ltd.
• Lannett Company Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• フルオキセチン市場2029：新たな機会を提供する国
• フルオキセチン市場2029：新たな機会を提供するセグメント
• フルオキセチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Fluoxetine, classified as a selective serotonin reuptake inhibitor (SSRI), is widely utilized as an antidepressant and for various psychiatric conditions. Its mechanism involves boosting serotonin levels, a neurotransmitter crucial for regulating mood, emotions, and behavior in the brain. Prescribed commonly for depression, fluoxetine aids in enhancing sleep, appetite, and energy levels among individuals with major depressive disorder.

Fluoxetine is available in diverse forms such as tablets, solutions, capsules, and syrups. Tablets, a solid oral dosage form, dissolve in the stomach upon ingestion and are administered to adults, children, and the elderly. This medication is frequently prescribed for conditions including obsessive-compulsive disorder, panic disorder, depression, and bulimia nervosa. It is utilized across various settings such as clinics and hospitals.

The fluoxetine market research report is one of a series of new reports from The Business Research Company that provides fluoxetine market statistics, including fluoxetine industry global market size, regional shares, competitors with a fluoxetine market share, detailed fluoxetine market segments, market trends and opportunities, and any further data you may need to thrive in the fluoxetine industry. This fluoxetine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The fluoxetine market size has grown strongly in recent years. It will grow from $0.99 billion in 2024 to $1.04 billion in 2025 at a compound annual growth rate (CAGR) of 5.1%. The growth in the historic period can be attributed to increased rates of depression and anxiety disorders, enhanced awareness and de-stigmatization of mental health issues, improved healthcare infrastructure, an aging global population, and the availability of cost-effective generic fluoxetine.

The fluoxetine market size is expected to see steady growth in the next few years. It will grow to $1.25 billion in 2029 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to government initiatives and funding for mental health programs, public health campaigns promoting mental well-being, increasing discussion and awareness of mental health issues on social media platforms, the rise of online pharmacies, cultural shifts towards accepting and addressing mental health issues. Major trends in the forecast period include advances in diagnostic methods leading to early detection, the rise of telemedicine facilitates, advances in drug delivery systems, AI and machine learning are increasingly used in drug discovery and development, and developments in pharmacogenomics.

The increasing incidence of mental health disorders is anticipated to drive the expansion of the fluoxetine market in the future. Mental health disorders encompass a wide spectrum of conditions affecting cognitive, emotional, and behavioral functions, resulting in distress or impairment in daily life. Factors contributing to the rise in these disorders include societal pressures, economic challenges, lifestyle shifts, and improved awareness and diagnosis. Fluoxetine is utilized in the treatment of mental health disorders because it alleviates symptoms by enhancing serotonin levels in the brain, crucial for regulating mood and emotions. For example, a survey conducted in November 2022 by the National Health Service, a UK government-funded healthcare system, revealed that approximately 18.0% of children aged 7 to 16 and 22.0% of young individuals aged 17 to 24 potentially had a mental disorder in 2022. Specifically, the prevalence of likely mental disorders among young people aged 17 to 19 increased from 17.4% in 2021 to 25.7% in 2022. Consequently, the rising prevalence of mental health disorders is a significant factor propelling the growth of the fluoxetine market.

The fluoxetine market is anticipated to experience growth due to the rise in healthcare expenditure. This increase is driven by factors such as the escalating costs of advanced medical technologies, aging populations, and the prevalence of chronic diseases. As healthcare spending rises, it improves the accessibility and affordability of medications such as fluoxetine, which benefits patients requiring treatment for depression and anxiety disorders by enhancing access and adherence. Consequently, this can lead to better mental health outcomes overall and reduce long-term healthcare expenses. For example, in January 2024, healthcare expenditure in the US surged by 4.1% in 2022 to $4.5 trillion, marking a faster growth rate compared to the 3.2% increase seen in 2021, as reported by the National Institutes of Health, a US government agency.

Key players in the fluoxetine market are concentrating on innovating products such as fluoxetine tablets for treating various mental health disorders such as major depressive disorder. Fluoxetine tablets contain fluoxetine hydrochloride, an antidepressant classified as a selective serotonin reuptake inhibitor (SSRI). In April 2024, Strides Pharma Global Pte. Limited, a Singapore-based pharmaceutical company, received approval from the United States Food and Drug Administration (USFDA) for Fluoxetine Tabs 10 mg and 20 mg. This approval expands the company's fluoxetine product line by introducing tablets alongside the already-approved capsules. Fluoxetine, an SSRI, is used to treat conditions such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), bulimia nervosa, and panic disorder with or without agoraphobia. The introduction of fluoxetine tablets broadens the treatment options within the company's fluoxetine portfolio, providing patients and healthcare providers with more flexibility and choices in managing these mental health disorders.

Major companies operating in the fluoxetine market are Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hetero Ltd., Torrent Pharmaceuticals GmbH, Aurobindo Pharma, Cadila Pharmaceuticals Ltd., Dr. Reddy's Laboratories Limited, Apotex Inc., Amneal Pharmaceuticals Inc., Lupin Ltd., Glenmark Pharmaceuticals Inc., Alvogen, Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., PERRIGO Company plc, Wockhardt Ltd., Jubilant Life Sciences Ltd., Lannett Company Inc., Mayne Pharma International Pty Ltd., Par Pharmaceutical Companies Inc., Zydus Pharmaceuticals USA Inc., Ascend Laboratories LLC

North America was the largest region in the fluoxetine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fluoxetine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fluoxetine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fluoxetine market consists of sales of fluoxetine hydrochloride tablets, fluoxetine powder, and fluoxetine injection. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fluoxetine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fluoxetine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for fluoxetine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fluoxetine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Dosage Form: Tablet; Solution; Capsule; Syrup; Other Dosage Forms
• 2) By Route Of Administration: Oral; Other Routes Of Administration
• 3) By Demographic: Adult; Pediatric; Geriatric
• 4) By Application: Obsessive-Compulsive Disorder; Panic Disorder; Depression; Bulimia Nervosa; Other Applications
• 5) By End User: Clinic; Hospital; Other End Users
• Subsegments:
• 1) By Tablet: Regular Tablets; Extended-Release Tablets
• 2) By Solution: Oral Solution
• 3) By Capsule: Standard Capsules; Delayed-Release Capsules
• 4) By Syrup: Oral Syrup
• 5) By Other Dosage Forms: Injection Form; Topical Form
• Companies Mentioned: Eli Lilly and Company; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Hetero Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Fluoxetine Market Characteristics

3. Fluoxetine Market Trends And Strategies

4. Fluoxetine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Fluoxetine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Fluoxetine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Fluoxetine Market Growth Rate Analysis
• 5.4. Global Fluoxetine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Fluoxetine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Fluoxetine Total Addressable Market (TAM)

6. Fluoxetine Market Segmentation

• 6.1. Global Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Solution
• Capsule
• Syrup
• Other Dosage Forms
• 6.2. Global Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Other Routes Of Administration
• 6.3. Global Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Pediatric
• Geriatric
• 6.4. Global Fluoxetine Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Obsessive-Compulsive Disorder
• Panic Disorder
• Depression
• Bulimia Nervosa
• Other Applications
• 6.5. Global Fluoxetine Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinic
• Hospital
• Other End Users
• 6.6. Global Fluoxetine Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Regular Tablets
• Extended-Release Tablets
• 6.7. Global Fluoxetine Market, Sub-Segmentation Of Solution, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Solution
• 6.8. Global Fluoxetine Market, Sub-Segmentation Of Capsule, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Standard Capsules
• Delayed-Release Capsules
• 6.9. Global Fluoxetine Market, Sub-Segmentation Of Syrup, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Syrup
• 6.10. Global Fluoxetine Market, Sub-Segmentation Of Other Dosage Forms, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injection Form
• Topical Form

7. Fluoxetine Market Regional And Country Analysis

• 7.1. Global Fluoxetine Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Fluoxetine Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Fluoxetine Market

• 8.1. Asia-Pacific Fluoxetine Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Fluoxetine Market

• 9.1. China Fluoxetine Market Overview
• 9.2. China Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Fluoxetine Market

• 10.1. India Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Fluoxetine Market

• 11.1. Japan Fluoxetine Market Overview
• 11.2. Japan Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Fluoxetine Market

• 12.1. Australia Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Fluoxetine Market

• 13.1. Indonesia Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Fluoxetine Market

• 14.1. South Korea Fluoxetine Market Overview
• 14.2. South Korea Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Fluoxetine Market

• 15.1. Western Europe Fluoxetine Market Overview
• 15.2. Western Europe Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Fluoxetine Market

• 16.1. UK Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Fluoxetine Market

• 17.1. Germany Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Fluoxetine Market

• 18.1. France Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Fluoxetine Market

• 19.1. Italy Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Fluoxetine Market

• 20.1. Spain Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Fluoxetine Market

• 21.1. Eastern Europe Fluoxetine Market Overview
• 21.2. Eastern Europe Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Fluoxetine Market

• 22.1. Russia Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Fluoxetine Market

• 23.1. North America Fluoxetine Market Overview
• 23.2. North America Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Fluoxetine Market

• 24.1. USA Fluoxetine Market Overview
• 24.2. USA Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Fluoxetine Market

• 25.1. Canada Fluoxetine Market Overview
• 25.2. Canada Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Fluoxetine Market

• 26.1. South America Fluoxetine Market Overview
• 26.2. South America Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Fluoxetine Market

• 27.1. Brazil Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Fluoxetine Market

• 28.1. Middle East Fluoxetine Market Overview
• 28.2. Middle East Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Fluoxetine Market

• 29.1. Africa Fluoxetine Market Overview
• 29.2. Africa Fluoxetine Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Fluoxetine Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Fluoxetine Market, Segmentation By Demographic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Fluoxetine Market Competitive Landscape And Company Profiles

• 30.1. Fluoxetine Market Competitive Landscape
• 30.2. Fluoxetine Market Company Profiles
  • 30.2.1. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sun Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Hetero Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Fluoxetine Market Other Major And Innovative Companies

• 31.1. Torrent Pharmaceuticals GmbH
• 31.2. Aurobindo Pharma
• 31.3. Cadila Pharmaceuticals Ltd.
• 31.4. Dr. Reddy's Laboratories Limited
• 31.5. Apotex Inc.
• 31.6. Amneal Pharmaceuticals Inc.
• 31.7. Lupin Ltd.
• 31.8. Glenmark Pharmaceuticals Inc.
• 31.9. Alvogen
• 31.10. Alembic Pharmaceuticals Limited
• 31.11. Accord Healthcare Ltd.
• 31.12. PERRIGO Company plc
• 31.13. Wockhardt Ltd.
• 31.14. Jubilant Life Sciences Ltd.
• 31.15. Lannett Company Inc.

32. Global Fluoxetine Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Fluoxetine Market

34. Recent Developments In The Fluoxetine Market

35. Fluoxetine Market High Potential Countries, Segments and Strategies

• 35.1 Fluoxetine Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Fluoxetine Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Fluoxetine Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer